Niamh O'Luanaigh

Biosensia Ltd. develops multiplexing point of care in vitro diagnostics platform. It offers RapiPlex, a point-of-care diagnosis system based on a set of proprietary technologies capable of producing quantitative and qualitative laboratory quality test results. The company was founded by Gareth Redmond and Gabriel Crean in 2009 and is headquartered in Dublin, Ireland.

BBI Diagnostics Group Ltd. develops and manufactures raw materials and finished test platforms for the in-vitro diagnostics market. The firm’s products include cell culture reagents, conjugates, depleted serum, disease state plasma, enzymes, finished kits, gold nanoparticles, monoclonal antibodies, normal serums, patient samples, polyclonal antibodies, recombinant antibodies, silver nanoparticles, biothreat and explosives antibodies. It’s services include custom conjugation, lateral flow assay development, 3DNA pushing assay sensitivity to the limit, test optimisation, atomo rapid platform and the novarum reader. The company was founded by John Chandler in 1986 and is headquartered in Cardiff, the United Kingdom.